Assessing mortality risk in COPD.
D000206:Actuarial Analysis; D000420:Albuterol / Q000031:analogs & derivatives / Q000627:therapeutic use; D000730:Androstadienes / Q000627:therapeutic use; D015992:Body Mass Index; D016535:Bronchial Hyperreactivity / Q000150:complications; D001993:Bronchodilator Agents / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000150:complications; D004338:Drug Combinations; D004417:Dyspnea / Q000150:complications; D015444:Exercise; D000068297:Fluticasone-Salmeterol Drug Combination; D006801:Humans; D006935:Hypercapnia / Q000150:complications; D029424:Pulmonary Disease, Chronic Obstructive / Q000150:complications / Q000188:drug therapy / Q000401:mortality*; D012129:Respiratory Function Tests; D018570:Risk Assessment; D016540:Smoking Cessation
D000730:Androstadienes; D001993:Bronchodilator Agents; D004338:Drug Combinations; D000068297:Fluticasone-Salmeterol Drug Combination; D000420:Albuterol